Pharmaceutical giant Merck anticipates that the manufacturing timeline for its innovative, personalized cancer vaccine, developed in partnership with Moderna, will significantly accelerate as production methods evolve. Currently requiring a complex six-week turnaround from initial tumor sequencing to hospital delivery, the vaccine is engineered to target specific mutations unique to each individual patient rather than employing […]